Can investigational treatments address unmet needs in mCRPC?
Can investigational therapies enable mCRPC treatment in an “all-comer” patient population? Professor Axel Merseburger (University Hospital Schleswig-Holstein, Campus Lübeck, Germany) reflects on this and other possibilities. View transcript.
Barriers to uptake of clinical practice guidelines for mCRPC
Professor Merseburger discusses some key challenges in following clinical practice guideline recommendations for mCRPC management, and why guideline uptake remains low. View transcript.
Important considerations about patient populationsin mCRPC trials
Dr Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, USA) identifies an important caveat for patient populations in phase 3 first-line mCRPC trials, which he considers “the single most debated point” at conferences. View transcript.
Differences in clinical trial design for PARP inhibitors and novel hormonal therapies
Dr Agarwal describes similarities and differences in the design of the MAGNITUDE, TALAPRO-2, and PROpel mCRPC trials, noting all trials were “inherently different” and their similarities stop after three common features. View transcript.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
